MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Boston Scientific Corp.

Abrir

SetorSaúde

101.38 0.83

Visão Geral

Variação de preço das ações

24h

Atual

Mín

100.42

Máximo

101.95

Indicadores-chave

By Trading Economics

Rendimento

-138M

562M

Vendas

352M

4.6B

P/E

Médio do Setor

74.864

57.333

EPS

0.7

Margem de lucro

12.322

Funcionários

53,000

EBITDA

-41M

1B

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+18.99% upside

Dividendos

By Dow Jones

Próximos Ganhos

23 de jul. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-14B

138B

Abertura anterior

100.55

Fecho anterior

101.38

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Boston Scientific Corp. Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

23 de abr. de 2025, 12:16 UTC

Ganhos
Grandes Movimentos do Mercado

Boston Scientific Shares Higher on Rosy Outlook, 1Q Beats

3 de mar. de 2025, 12:35 UTC

Aquisições, Fusões, Aquisições de Empresas

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million

5 de fev. de 2025, 12:23 UTC

Ganhos

Boston Scientific 4Q Profit Up on Strong Cardio Device Sales

23 de abr. de 2025, 10:32 UTC

Ganhos

Boston Scientific Sees 2Q Reported Sales Up 17.5%-19.5%, Organic Sales Up 13%-15% >BSX

23 de abr. de 2025, 10:31 UTC

Ganhos

Boston Scientific Sees 2025 Reported Sales Up 15%-17%, Organic Sales Up 12%-14% >BSX

23 de abr. de 2025, 10:30 UTC

Ganhos

Boston Scientific 1Q EPS 45c >BSX

23 de abr. de 2025, 10:30 UTC

Ganhos

Boston Scientific 1Q Adj EPS 75c >BSX

23 de abr. de 2025, 10:30 UTC

Ganhos

Boston Scientific Sees FY Adj EPS $2.87-Adj EPS $2.94 >BSX

23 de abr. de 2025, 10:30 UTC

Ganhos

Boston Scientific 1Q Sales $4.66B >BSX

23 de abr. de 2025, 10:30 UTC

Ganhos

Boston Scientific Sees 2Q Adj EPS 71c-Adj EPS 73c >BSX

23 de abr. de 2025, 10:30 UTC

Ganhos

Boston Scientific Sees 2Q EPS 45c-EPS 47c >BSX

23 de abr. de 2025, 10:30 UTC

Ganhos

Boston Scientific 1Q Organic Sales Up 18.2% >BSX

23 de abr. de 2025, 10:30 UTC

Ganhos

Boston Scientific Sees FY EPS $1.86-EPS $1.93 >BSX

3 de mar. de 2025, 11:59 UTC

Aquisições, Fusões, Aquisições de Empresas

Boston Scientific to Pay Up to Additional $180 Million Upon Achievement of Regulatory Milestone >BSX

3 de mar. de 2025, 11:58 UTC

Aquisições, Fusões, Aquisições de Empresas

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million >BSX

3 de mar. de 2025, 11:58 UTC

Aquisições, Fusões, Aquisições de Empresas

Boston Scientific Announces Agreement To Acquire SoniVie Ltd. >BSX

5 de fev. de 2025, 21:33 UTC

Ganhos

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

5 de fev. de 2025, 15:20 UTC

Ganhos

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

5 de fev. de 2025, 11:39 UTC

Ganhos

Boston Scientific Sees 1Q Organic Sales Up 14%-16% >BSX

5 de fev. de 2025, 11:39 UTC

Ganhos

Boston Scientific Sees 1Q Sales Up 17%-19% >BSX

5 de fev. de 2025, 11:38 UTC

Ganhos

Boston Scientific Sees 2025 Organic Sales Up 10%-12% >BSX

5 de fev. de 2025, 11:38 UTC

Ganhos

Boston Scientific Sees 2025 Sales Up 12.5%-14.5% >BSX

5 de fev. de 2025, 11:37 UTC

Ganhos

Boston Scientific 4Q Organic Sales Up 19.5% >BSX

5 de fev. de 2025, 11:37 UTC

Ganhos

Boston Scientific 4Q Adj EPS 70c >BSX

5 de fev. de 2025, 11:37 UTC

Ganhos

Boston Scientific Sees FY EPS $1.86-EPS $1.93 >BSX

5 de fev. de 2025, 11:37 UTC

Ganhos

Boston Scientific 4Q Sales $4.56B >BSX

5 de fev. de 2025, 11:37 UTC

Ganhos

Boston Scientific Sees FY Adj EPS $2.80-Adj EPS $2.87 >BSX

5 de fev. de 2025, 11:37 UTC

Ganhos

Boston Scientific Sees 1Q Adj EPS 66c-Adj EPS 68c >BSX

5 de fev. de 2025, 11:37 UTC

Ganhos

Boston Scientific Sees 1Q EPS 43c-EPS 45c >BSX

5 de fev. de 2025, 11:37 UTC

Ganhos

Boston Scientific 4Q EPS 38c >BSX

Comparação entre Pares

Variação de preço

Boston Scientific Corp. Previsão

Preço-alvo

By TipRanks

18.99% parte superior

Previsão para 12 meses

Média 120.35 USD  18.99%

Máximo 135 USD

Mínimo 110 USD

Com base em 23 analistas de Wall Street que oferecem metas de preço de 12 meses para Boston Scientific Corp. - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

23 ratings

22

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

95.25 / 102.37Suporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

No Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.